Tetherex Pharmaceuticals Overview
- Founded
-
2002
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$50M
- Investors
-
9
Tetherex Pharmaceuticals General Information
Description
Producer of medicinal drugs designed to treat thrombosis, inflammation, and tumor metastasis. The company's drugs develop novel first-in-class therapeutics targeting cell adhesion proteins in thrombotic, inflammatory, and oncologic diseases to work on the molecular mechanisms of cell adhesion and inflammation, enabling patients who suffer these afflictions to enjoy descent and long lives.
Contact Information
Website
www.tetherex.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 840 Research Parkway
- Suite 516
- Oklahoma City, OK 73104
- United States
+1 (405) 000-0000
Tetherex Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 06-Mar-2018 | $50M | 000.00 | 00000 | Completed | Clinical Trials - General |
| 6. Debt - General | 09-Oct-2015 | 000 | 000.00 | Completed | Clinical Trials - General | |
| 5. Later Stage VC (Series A) | 09-Feb-2015 | 00.000 | 000.00 | Completed | Clinical Trials - General | |
| 4. Later Stage VC (Series A) | 17-Sep-2012 | 0000 | 0000 | 000.00 | Completed | Clinical Trials - General |
| 3. Angel (individual) | 01-Apr-2010 | 0000 | 0000 | Completed | Clinical Trials - General | |
| 2. Grant | 16-Jun-2009 | $3.2M | Completed | Clinical Trials - General | ||
| 1. Grant | 28-Apr-2009 | $300K | Completed | Clinical Trials - General |
Tetherex Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00.0 | 000 | 000 | 00 | 000 | 00.000 |
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Tetherex Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Producer of medicinal drugs designed to treat thrombosis, inflammation, and tumor metastasis. The company's drugs develo
Drug Discovery
Oklahoma City, OK
000.00
0000
0000-00-00
00000000000
000.00
0000 0
aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. E
0000 000000000
San Diego, CA
00
As of 0000
00000
00000000
00000
00000
sequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000 000000000
Tucson, AZ
00
As of 0000
000.00
000
0000-00-00
0000000000 0
000.00
Add Comparison
Tetherex Pharmaceuticals Competitors (94)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| aTyr Pharma | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
| 00000 000000 | Venture Capital-Backed | Tucson, AZ | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 000.00 | 0000000000 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | Boston, MA | 0000 | 00.000 | 000000&0 |
Tetherex Pharmaceuticals Patents
Tetherex Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2009246166-B2 | Anti-psgl-1 antibodies and methods of identification and use | Active | 15-May-2008 | 00000000000 | |
| AU-2009246166-A1 | Anti-psgl-1 antibodies and methods of identification and use | Active | 15-May-2008 | 00000000000 | |
| CA-2724415-A1 | Anti-psgl-1 antibodies and methods of identification and use | Active | 15-May-2008 | 00000000000 | |
| CA-2724415-C | Anti-psgl-1 antibodies and methods of identification and use | Active | 15-May-2008 | 00000000000 | |
| EP-2291536-A4 | Anti-psgl-1 antibodies and methods of identification and use | Inactive | 15-May-2008 | C07K16/2896 |
Tetherex Pharmaceuticals Executive Team (9)
Tetherex Pharmaceuticals Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Keiser | Self | Board Member | 000 0000 |
| Philip Jones MD | Self | Board Member | 000 0000 |
| Rodger McEver MD | Tetherex Pharmaceuticals | Co-Founder & Board Member | 000 0000 |
| Scott Rollins Ph.D | Tetherex Pharmaceuticals | Chief Executive Officer & Chairman | 000 0000 |
| Todd Foley | MPM Capital | Board Member | 000 0000 |
Tetherex Pharmaceuticals Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Mayo Clinic Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Philip Jones | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| i2E | Venture Capital | Minority | 000 0000 | 000000 0 | |
| MPM Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Oklahoma Life Science Fund | Venture Capital | Minority | 000 0000 | 000000 0 |